DZ Bank
RARE icon

DZ Bank’s Ultragenyx Pharmaceutical RARE Stock Holding History

DZ Bank’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$101K Buy
+3,032
New +$75.3K ﹤0.01% 988
2026
Q1 		– Sell
-67,339
Closed -$1.55M – 1051
2025
Q4 		$1.55M Sell
67,339
-213,127
-76% -$7.01M ﹤0.01% 658
2025
Q3 		$8.44M Sell
280,466
-30,635
-10% -$919K 0.01% 414
2025
Q2 		$11.3M Hold
311,101
– – 0.01% 357
2025
Q1 		$11.3M Sell
311,101
-35,496
-10% -$1.48M 0.01% 335
2024
Q4 		$14.6M Buy
346,597
+51,874
+18% +$2.57M 0.01% 282
2024
Q3 		$16.4M Hold
294,723
– – 0.02% 292
2024
Q2 		$12.1M Buy
294,723
+137,447
+87% +$5.87M 0.01% 317
2024
Q1 		$7.34M Buy
+157,276
New +$7.42M 0.01% 407
2018
Q2 		– Sell
-23,909
Closed -$1.22M – 1038
2018
Q1 		$1.22M Buy
+23,909
New +$1.2M ﹤0.01% 620

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

DZ Bank's RARE Position: Q2 2026 in Review

DZ Bank opened a new position in Ultragenyx Pharmaceutical (RARE) in Q2 2026: 3,032 shares worth $101K. The stake represents ﹤0.01% of the portfolio and ranks #988 among its holdings. This is a return to the name: DZ Bank previously reported a position in RARE as recently as Q4 2025.

DZ Bank first reported a position in RARE in Q1 2018 and has held it in 10 quarters since. The position peaked at $16.4M in Q3 2024. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • DZ Bank held 3,032 shares of Ultragenyx Pharmaceutical worth $101K as of Q2 2026.
  • Ultragenyx Pharmaceutical was a new DZ Bank position in Q2 2026.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of DZ Bank's portfolio in Q2 2026, its #988 holding.
  • DZ Bank first reported a position in Ultragenyx Pharmaceutical in Q1 2018 and has held it in 10 quarters since.
  • DZ Bank's Ultragenyx Pharmaceutical position peaked at $16.4M in Q3 2024.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on DZ Bank's 13F filing for Q2 2026, filed 14 Aug 2026.